Table 1.
Characteristics at Trial Entry Among Participants Included in Analysis
| Characteristic | START Participants After Quality Control, No. (%)a (n = 2440) |
|---|---|
| Age median (IQR), y | 37 (29–45) |
| Sex | |
| Female | 489 (20.0) |
| Male | 1951 (80.0) |
| Race/ethnic group | |
| Black | 572 (23.4) |
| Hispanic | 418 (17.1) |
| Asian | 13 (0.5) |
| White | 1398 (57.3) |
| Other | 39 (1.6) |
| Geographic region | |
| Africa | 339 (13.9) |
| Australia | 91 (3.7) |
| Europe and Israel | 1136 (46.6) |
| Latin America | 423 (17.3) |
| United States | 451 (18.5) |
| Mode of HIV infection | |
| Injection drug use | 45 (1.8) |
| Sex with same sex | 1560 (63.9) |
| Sex with opposite sex | 721 (29.5) |
| Other | 114 (4.7) |
| Time since HIV diagnosis, median (IQR), y | 1.1 (0.4–3.0) |
| Recent infection (within 6 mo) | 165 (6.8) |
| CD4+ cell count, median (IQR), cells/μL | 651 (585–697) |
| HIV load, median (IQR), copies/mL | 14 734 (3500–45 796) |
Abbreviations: HIV, human immunodeficiency virus; IQR, interquartile range; START, Strategic Timing of AntiRetroviral Treatment.
aData represent no. (%) of participants unless otherwise specified.